XBiotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 82
- Market Cap
- $198M
- Website
- http://www.xbiotech.com
- Introduction
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT06590090
Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06526377
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT05363891
- Locations
- 🇺🇸
Medvin Clinical Research, Tujunga, California, United States
🇺🇸T. Joseph Raoof MD, INC, Encino, California, United States
🇺🇸Desert Medical Advances, Rancho Mirage, California, United States
Natrunix Versus Methotrexate in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Natrunix placebo with MTX (+folate)Drug: Natrunix with MTX placebo (+folate)
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05363917
Natrunix Safety PK Study in Healthy Volunteers
- Conditions
- Pharmacokinetics
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05099510
- Locations
- 🇺🇸
BioBehavioral Research of Austin, A Telemed2U Company, Austin, Texas, United States
- Prev
- 1
- 2
- Next
News
XBiotech Halts Rheumatology Program Following Phase II Trial Irregularities with Natrunix
XBiotech has paused its rheumatology program after a Phase II trial of Natrunix for rheumatoid arthritis failed to meet its primary endpoint.
BioAge Labs Faces Securities Lawsuits Following Azelaprag Trial Discontinuation
• BioAge Labs is under investigation for potential securities law violations after discontinuing its Phase 2 trial of azelaprag due to safety concerns. • Multiple law firms have announced investigations and class action lawsuits on behalf of investors who suffered losses following the trial halt. • The STRIDES Phase 2 trial was terminated after liver transaminitis was observed in participants, leading to a significant drop in BioAge's stock price. • Investors who purchased BioAge securities during the IPO period have until March 10, 2025, to seek lead plaintiff status in the class action.